# Tirzepatide Weight Loss: The Trial Evidence — Pharmacy Tirzepatide

> Tirzepatide weight loss: SURMOUNT-1 produced -20.9% at 15 mg vs -3.1% placebo over 72 weeks. SURMOUNT-5 showed -20.2% vs -13.7% for semaglutide. The full evidence, cited.

## The short version

Tirzepatide weight loss in the SURMOUNT-1 trial: participants with obesity and without diabetes lost an average of 20.9% of body weight at the highest dose (15 mg) over 72 weeks, compared to 3.1% with placebo. That means someone who weighed 250 pounds would lose roughly 52 pounds on average. SURMOUNT-5 then tested tirzepatide head-to-head against semaglutide in 751 people with obesity and found tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide — a difference of about 6.5 percentage points. The numbers are large by any prior standard in weight-loss pharmacology. This page documents where they come from.

## Tirzepatide weight loss: SURMOUNT-1 (72-week pivotal trial in obesity)

SURMOUNT-1 enrolled 2,539 adults with obesity (BMI ≥30, or ≥27 with at least one weight-related complication) and without diabetes in a 72-week double-blind randomised controlled trial [4]. Participants were randomised to once-weekly subcutaneous tirzepatide at 5, 10, or 15 mg — starting at 2.5 mg and titrating over 20 weeks — or matching placebo.

**Mean body-weight change at week 72:**
- Tirzepatide 5 mg: −15.0%
- Tirzepatide 10 mg: −19.5%
- Tirzepatide 15 mg: −20.9%
- Placebo: −3.1%

**Proportion achieving ≥5% weight loss:**
- 5 mg: 85%
- 10 mg: 89%
- 15 mg: 91%
- Placebo: 35%

**Proportion achieving ≥20% weight loss:**
- 5 mg: 30%
- 10 mg: 50%
- 15 mg: 57%
- Placebo: 3%

The most common adverse events were gastrointestinal — nausea, diarrhea, vomiting, and constipation — and were mostly mild to moderate, occurring primarily during dose escalation. Adverse events leading to discontinuation occurred in 4.3% (5 mg), 7.1% (10 mg), and 6.2% (15 mg) versus 2.6% with placebo [4].

## SURMOUNT-5: tirzepatide weight loss versus semaglutide head-to-head

SURMOUNT-5 was designed specifically to compare tirzepatide and semaglutide head-to-head for weight loss in adults with obesity without type 2 diabetes [5]. Phase 3b, open-label, 751 participants, 72 weeks. Both agents were titrated to maximum tolerated dose: tirzepatide 10 or 15 mg, semaglutide 1.7 or 2.4 mg.

**Least-squares mean body-weight change at week 72:**
- Tirzepatide: −20.2%
- Semaglutide: −13.7%
- Difference: approximately 6.5 percentage points (P<0.001)

Tirzepatide produced greater reductions in waist circumference and higher proportions reaching every weight-loss threshold measured: ≥10%, ≥15%, ≥20%, and ≥25% weight loss. Quality-of-life improvements were also greater with tirzepatide, particularly in physical-function domains and overall General Health [37].

For the full [tirzepatide vs semaglutide](/vs-semaglutide) comparison including HbA1c data from SURPASS-2, see the dedicated comparison page.

## How tirzepatide weight loss works: the dual-receptor mechanism

Tirzepatide's weight loss results from three overlapping mechanisms driven by dual GIP and GLP-1 receptor engagement:

1. **Appetite reduction** — Both GLP-1R and GIPR agonism suppress appetite via central nervous system pathways. In the CNS, GIPR agonism also attenuates nausea (the main side effect that limits dose and therefore efficacy), which may allow larger effective doses than single-receptor agents [10].

2. **Reduced caloric intake** — The quieting of food-related thoughts ('food noise'), reduced portion satisfaction, and slowed gastric emptying reduce total caloric intake without requiring conscious restriction [1].

3. **Metabolic effects** — GIPR agonism in adipose tissue favours metabolically advantageous lipid buffering and may protect against ectopic fat deposition, improving insulin sensitivity independently of weight reduction [10].

The question of whether muscle or fat preferentially drives the weight change is addressed in the SURMOUNT-1 DXA substudy, which found approximately 25% lean mass and 75% fat mass in the weight lost at 15 mg. Active investigation into resistance training protocols to preserve muscle mass during tirzepatide treatment is ongoing [21, 23].

## What the SURMOUNT-REAL UK pragmatic trial will add

The SURMOUNT-REAL UK trial is a five-year phase 4 pragmatic randomised controlled trial enabled by integrated electronic healthcare records in Greater Manchester, UK. Approximately 3,000 participants have been randomised 1:1 to tirzepatide plus standard-of-care versus standard-of-care alone. The primary endpoint is percent body-weight change from baseline to month 24. Key secondary endpoints include time to onset of type 2 diabetes (to month 60), obesity complications, quality of life, healthcare resource use, and productivity [38]. Results will provide real-world efficacy and effectiveness data in a National Health Service population.

Full citation data and the methodology for all studies cited here are on the [Tirzepatide references](/references) page.

---

A plain-numbers reading desk for the tirzepatide trial record — every figure traced to its published source.